Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review

Garrett K. Berger, Ali McBride, Stephanie Lawson, Kelsey Royball, Seongseok Yun, Kevin Gee, Irbaz Bin Riaz, Ahlam A. Saleh, Soham Puvvada, Faiz Anwer

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations

Abstract

Background Brentuximab vedotin (BV) is an antibody-drug conjucate (ADC) comprising a CD30-directed antibody, conjugated to the microtubule-disrupting agent MMAE via a protease cleavable linker. BV is FDA approved for use in relapsed classical Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL). There are multiple publications for its utility in other malignancies such as diffuse large B-cell lymphoma (DLBCL), mycosis fungoides (MF), Sézary syndrome (SS), T-cell lymphomas (TCL), primary mediastinal lymphoma (PMBL), and post-transplant lymphoproliferative disorders (PTLD). We believe that BV could potentially provide a strong additional treatment option for patients suffering from NHL. Objective Perform a systematic review on the use of BV in non-Hodgkin lymphoma (NHL) and other CD30+ malignancies in humans. Data sources We searched various databases including PubMed (1946–2015), EMBASE (1947–2015), and Cochrane Central Register of Controlled Trials (1898–2015). Eligibility criteria Inclusion criteria specified all studies and case reports of NHLs in which BV therapy was administered. Included studies A total of 28 articles met these criteria and are summarized in this manuscript. Conclusion Our findings indicate that BV induces a variety of responses, largely positive in nature and variable between NHL subtypes. With additional, properly powered prospective studies, BV may prove to be a strong candidate in the treatment of various CD30+ malignancies.

Original languageEnglish (US)
Pages (from-to)42-50
Number of pages9
JournalCritical Reviews in Oncology/Hematology
Volume109
DOIs
StatePublished - Jan 1 2017

Keywords

  • Brentuximab vedotin
  • CD30
  • Relapse or refractory NHL

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review'. Together they form a unique fingerprint.

Cite this